We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

News

06 Nov 19
AC Immune Hosts Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases
Attachments:
PDF Version
24 Oct 19
AC Immune to Host Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases
Attachments:
PDF Version
20 Sep 19
AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program
Attachments:
PDF Version
17 Sep 19
AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620
Attachments:
PDF Version
04 Sep 19
AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson’s Disease Diagnostic Imaging Agent
Attachments:
PDF Version
14 Aug 19
AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update
Attachments:
PDF Version
12 Aug 19
AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases
Attachments:
PDF Version
01 Aug 19
AC Immune Initiates Ph1b/2a Study of Anti-Phospho-Tau Vaccine in Alzheimer’s Disease
Attachments:
PDF Version
17 Jul 19
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
Attachments:
PDF Version
11 Jul 19
AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome
Attachments:
PDF Version
28 Jun 19
AC Immune Announces Election of New Chairman of the Board at Annual General Meeting
Attachments:
PDF Version
27 Jun 19
AC Immune to Host Key Opinion Leader Meeting on Treating Alzheimer’s in Down Syndrome
Attachments:
PDF Version
20 Jun 19
AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimer’s Disease
Attachments:
PDF Version
15 May 19
AC Immune Reports Q1 2019 Financial Results and Business Update
Attachments:
PDF Version
15 May 19
AC Immune Reports Q1 2019 Financial Results and Business Update
Attachments:
PDF Version
01 Apr 19
AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference
Attachments:
PDF Version
01 Apr 19
AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference
Attachments:
AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference
29 Mar 19
AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference
Attachments:
PDF Version
29 Mar 19
AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PDTM Conference
Attachments:
AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PDTM Conference
27 Mar 19
New Clinical Data on AC Immune’s Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD™ Conference
Attachments:
PDF Version
27 Mar 19
New Clinical Data on AC Immune's Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD(TM) Conference
Attachments:
New Clinical Data on AC Immune's Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD(TM) Conference
21 Mar 19
AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
Attachments:
AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
21 Mar 19
AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
Attachments:
PDF Version
04 Mar 19
AC Immune to Report Progress of Early-Stage Pipeline at AD/PD[TM] Congress
Attachments:
English
20 Feb 19
AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease
Attachments:
English
07 Feb 19
AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
Attachments:
English
30 Jan 19
AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease
Attachments:
English
03 Jan 19
AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer
Attachments:
English